查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014472

藥物濫用檢測市場：2026-2032年全球市場預測（按檢體類型、檢測技術、目標藥物和最終用戶分類）

Drug of Abuse Testing Market by Sample Type, Test Technology, Drug Panel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，藥物濫用檢測市場價值將達到 20 億美元，到 2026 年將成長到 21.4 億美元，到 2032 年將達到 33.4 億美元，複合年成長率為 7.58%。

主要市場統計數據
基準年 2025 20億美元
預計年份：2026年 21.4億美元
預測年份 2032 33.4億美元
複合年成長率 (%) 7.58%

對當前藥物濫用檢測現狀進行權威概述，重點關注不斷變化的使用模式、跨部門需求和實際挑戰。

藥物濫用檢測處於臨床實踐、法醫學、公共衛生監測和職場安全等多個領域的交匯點。過去十年，濫用物質種類日益多樣化、使用模式不斷變化以及監管力度加大，給實驗室和採購團隊帶來了巨大壓力，迫使他們採用更準確、快速和全面的分析方法。同時，終端使用者也越來越需要兼顧診斷準確性、出結果時間和成本效益的解決方案，這促使技術供應商在檢測方法、儀器和資料管理方面不斷創新。

技術突破、多樣化的檢體應用和數位化整合如何改變測試中的分析方法和相關人員的期望。

藥物濫用檢測領域正經歷著一場變革，這主要得益於分析化學的進步、對照護現場和快速確認流程日益成長的需求，以及目標藥物譜的多樣化。高解析度質譜和串聯式質譜質譜已從專業參考檢查室走向更廣泛的臨床和法醫學應用，從而能夠更可靠地檢測低濃度代謝物和新型合成化合物。同時，免疫檢測平台雖然仍然是經濟高效的篩檢工具，但如今擴大應用於混合工作流程中，其中層析法確認與初步篩檢相輔相成，以減少假陽性和假陰性結果。

我們將評估美國近期關稅措施對檢驗機構和供應商的採購、供應鏈韌性和業務連續性的影響。

美國近期推出的關稅措施和貿易政策調整對藥物濫用檢測供應鏈產生了切實的影響，尤其對那些從海外採購設備、耗材和試劑的實驗室和供應商而言更是如此。進口關稅的提高推高了層析法系統、質譜儀和專用一次性耗材的總成本，迫使採購團隊重新審查供應商合約、維護協議和總擁有成本 (TCO) 的計算。為此，一些機構正在加快庫存規劃，並考慮策略性地儲備關鍵試劑，以在高通量檢測環境中維持營運的連續性。

細分市場觀點：揭示檢體類型、分析平台、最終用戶需求和小組配置如何相互作用並影響營運選擇。

細分市場層面的趨勢揭示了不同檢體類型、分析技術、最終用戶和樣本組組成下不同的需求促進因素和技術要求。就檢體類型而言，毛髮分析通常用於法醫學和懲教機構，這些機構優先考慮回顧性接觸評估和較長的檢測期。另一方面，口腔拭子適用於現場篩檢，其採集方式微創，且與近期攝取量相關。尿液檢查由於其標準化的流程以及在工業和臨床環境中的廣泛應用，在臨床檢查室和醫院仍然十分重要。

將監管、基礎設施和普及因素與全球市場中不同的採用和擴散管道連結起來的區域分析。

區域差異反映了管理體制、醫療基礎設施的成熟度以及流行模式，這些因素共同影響部署路徑和服務提供模式。在美洲，法醫學和職場檢測框架相對成熟，並有強大的參考檢查室網路、多樣化的檢測項目和綜合報告系統提供支援。隨著相關人員兼顧公共衛生舉措和雇主主導的合規計劃，對高通量設備和證據管理系統的投資仍然是優先事項。

深入了解競爭力和服務差異化，從而決定公司如何在設備可靠性、檢查專案深度和數位化進步方面獲得價值。

在先進分析平台廣泛應用的競爭格局下，整合服務交付、可靠的售後服務以及合作研究夥伴關係關係至關重要。領先的儀器製造商在分析性能、使用者介面設計以及能夠降低變異性並簡化驗證的認證耗材生態系統方面展開競爭。對於那些面臨人員短缺且需要高通量運作的實驗室而言，能夠提供全面培訓、快速技術支援和靈活服務合約的供應商正運作受到青睞。

為產業領導者提供可操作的策略重點，以提高測試可靠性、供應鏈韌性、人力資源能力和監管合作。

藥物濫用檢測領域的領導者應優先考慮三項並行舉措，以增強韌性並抓住新的機會。首先，投資於模組化混合檢測架構，該架構將免疫檢測篩檢與基於層析法的確認性檢測相結合，並整合集中式和分散式檢體工作流程。這種方法使機構能夠在確保法醫學和臨床應用分析合法性的同時，最佳化成本和周轉時間。其次，透過供應商關係多元化、協商延長支援期限、確保關鍵耗材的儲備庫存，提高供應鏈透明度和合約柔軟性。這些措施可以降低進口關稅波動和物流中斷帶來的風險。

透明、多方面的研究途徑，結合相關人員訪談、技術檢驗數據和監管審查，為切實可行的建議奠定了基礎。

本執行摘要的研究基礎包括對實驗室負責人、採購經理和法醫學專家的訪談，以及對近期同行評審文獻、監管指南和公共衛生監測報告的二次分析。研究方法嚴謹，透過對多個獨立檢驗研究中記錄的檢測技術和儀器的性能特徵進行三角驗證，並結合定性見解。案例研究和供應商能力評估也被用於識別反覆出現的營運主題，例如工作流程整合、維護模式和培訓需求。

總結了綜合技術採用、供應鏈規劃和人力資源發展將如何決定未來測試的可靠性和影響。

總而言之，藥物濫用檢測領域正處於關鍵的轉折點，隨著技術能力、政策轉變和終端用戶多樣性的交織，操作規範正在重新定義。檢測實驗室和供應商在面臨整合先進分析平台的挑戰的同時，也有機會提供更可靠的檢測結果，從而為臨床護理、法醫學鑑定和公共做出更大貢獻。供應鏈壓力和貿易政策的變化要求積極主動的採購和緊急時應對計畫，而區域差異則需要因地制宜的部署策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依檢體類型分類的藥物濫用檢測市場

  • 頭髮
  • 口腔液
  • 尿

第9章：藥物濫用檢測市場及檢測技術

  • 層析法
    • GC-MS
    • LC-MS
      • LC-MS/MS
      • LC-TOF
  • 免疫檢測

第10章：藥物濫用檢測市場（依藥物檢測小組分類）

  • 可自訂面板
  • 擴充面板
  • 5種類型的面板
  • 10種面板

第11章：藥物濫用檢測市場：以最終用戶分類

  • 臨床檢查室
  • 懲教設施
  • 法醫學研究所
  • 醫院

第12章：藥物濫用檢測市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：藥物濫用偵測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 藥物濫用檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國藥物濫用檢測市場

第16章：中國藥物濫用檢測市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AccuBioTech Co., Ltd.
  • American Bio Medica Corporation
  • Bio-Rad Laboratories, Inc.
  • Clinical Reference Laboratory, LLC
  • Cordant Health Solutions Inc.
  • Danaher Corporation
  • Dragerwerk AG & Co. KGaA
  • Express Diagnostics International Inc.
  • F. Hoffmann-La Roche Ltd.
  • Laboratory Corporation of America Holdings（LabCorp）
  • LGC Group Holdings Ltd.
  • LifeLoc Technologies, Inc.
  • MP Biomedicals, LLC
  • Omega Laboratories, Inc.
  • OraSure Technologies, Inc.
  • Precision Diagnostics Inc.
  • Premier Biotech, Inc.
  • Psychemedics Corporation
  • Quest Diagnostics Incorporated
  • Randox Laboratories Ltd.
  • Siemens Healthineers AG
  • SureScreen Diagnostics Ltd.
  • Thermo Fisher Scientific Inc.
  • Wondfo Biotech Co., Ltd.
Product Code: MRR-4348D129FA91

The Drug of Abuse Testing Market was valued at USD 2.00 billion in 2025 and is projected to grow to USD 2.14 billion in 2026, with a CAGR of 7.58%, reaching USD 3.34 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.00 billion
Estimated Year [2026] USD 2.14 billion
Forecast Year [2032] USD 3.34 billion
CAGR (%) 7.58%

An authoritative orientation to the current drug of abuse testing environment highlighting evolving use patterns, cross-sector demands, and practical operational challenges

Drug of abuse testing sits at the intersection of clinical practice, forensic science, public health surveillance, and workplace safety. Over the past decade, escalating substance diversity, shifting patterns of use, and intensified regulatory scrutiny have placed testing laboratories and procurement teams under pressure to adopt more precise, rapid, and comprehensive analytical approaches. Meanwhile, end users increasingly demand solutions that balance diagnostic accuracy, turnaround time, and cost-efficiency, compelling technology providers to innovate across assay formats, instrumentation, and data management.

As stakeholders adapt, the ecosystem has expanded beyond traditional hospital and forensic settings to include correctional facilities, occupational health providers, and community-based screening programs. This diversification has implications for sample types, testing panels, and the relative mix of screening versus confirmatory methods. Consequently, laboratories must reconsider workflow design, quality assurance, and supply chain resilience while regulators update frameworks to address emerging synthetic drugs and novel psychoactive substances. In this context, understanding the interplay among sample collection choices, analytical platforms, and end-user requirements is essential for leaders aiming to align capabilities with evolving demand patterns and compliance expectations.

How technological breakthroughs, diversified sample applications, and digital integration are reshaping analytical approaches and stakeholder expectations in testing

The landscape of drug of abuse testing is undergoing transformative shifts driven by advancements in analytical chemistry, growing demand for point-of-care and rapid-confirmation workflows, and an expanding palette of targeted drug panels. High-resolution mass spectrometry and tandem mass spectrometry have migrated from specialized reference laboratories into broader clinical and forensic settings, enabling detection of low-concentration metabolites and emerging synthetic compounds with greater confidence. At the same time, immunoassay platforms continue to serve as cost-effective screening tools, but they now frequently operate in hybrid workflows where chromatographic confirmation complements initial screening to mitigate false positives and negatives.

Concurrently, sample-type innovation is changing downstream logistics and detection windows. Hair analysis offers long-term exposure insights that are valuable for retrospective investigations, while oral fluid presents a less invasive, on-site alternative that correlates well with recent use. Urine testing remains the backbone of many programs due to established protocols and extensive validation histories. These shifts also intersect with digital transformation: laboratory information management systems and connectivity solutions streamline result reporting, support chain-of-custody requirements, and integrate with electronic health records and corrections management systems. As policy frameworks evolve to address novel substances and privacy considerations, stakeholders must balance technological opportunity with ethical, legal, and operational constraints, ensuring that adoption enhances both analytical rigor and stakeholder trust.

Assessing how recent United States tariff measures are influencing procurement, supply chain resilience, and operational continuity for laboratories and vendors

Recent tariff actions and trade policy recalibrations in the United States are creating tangible implications for the drug of abuse testing supply chain, particularly for laboratories and vendors that rely on internationally sourced instrumentation, consumables, and reagents. Increased import duties elevate landed costs for chromatography systems, mass spectrometers, and specialized disposables, prompting procurement teams to reassess vendor agreements, maintenance contracts, and total cost of ownership calculations. In response, some organizations are accelerating inventory planning and exploring strategic stockpiling of critical reagents to maintain continuity in high-throughput testing environments.

Moreover, the tariffs are encouraging diversification of supplier portfolios and localized sourcing strategies. Instrument manufacturers and reagent suppliers are evaluating options to reconfigure manufacturing footprints, adjust component sourcing, or offer more flexible leasing and service models to mitigate buyer cost sensitivity. This shift has downstream effects on maintenance turnarounds, warranty coverage, and technical support channels, especially for facilities in remote or underserved regions. Importantly, regulatory compliance obligations do not relax in the face of cost pressures; laboratories must continue to satisfy validation and accreditation standards, which can complicate rapid vendor switching. Therefore, decision-makers should prioritize supply chain transparency, contractual safeguards, and contingency planning to preserve analytical integrity while managing cost volatility induced by tariff-driven market dynamics.

Segment-driven perspectives illuminating how sample types, analytical platforms, end-user requirements, and panel composition interact to shape operational choices

Segment-level dynamics reveal differentiated demand drivers and technical requirements across sample types, analytical technologies, end users, and panel configurations. When considering sample type, hair analysis caters to retrospective exposure assessment and tends to attract forensic and correctional use cases that prioritize extended detection windows, while oral fluid appeals to on-site screening contexts that require minimally invasive collection and correlation with recent consumption. Urine testing maintains prominence across clinical laboratories and hospitals because of standardized procedures and broad acceptance in occupational and clinical settings.

Turning to test technology, immunoassay methods retain relevance for high-throughput screening due to their operational simplicity and lower per-test cost, yet chromatography-based approaches are essential for specific confirmation workflows. Within chromatography, gas chromatography-mass spectrometry provides reliable analysis for volatile and thermally stable compounds, whereas liquid chromatography-mass spectrometry has emerged as the preferred modality for a broader array of polar and thermally labile analytes. Moreover, the liquid chromatography category itself bifurcates into tandem mass spectrometry configurations that deliver targeted quantitation and LC-QToF platforms that enable high-resolution screening and untargeted discovery of novel compounds. End-user segmentation also influences technology choices and service models: clinical laboratories and hospitals emphasize throughput, accreditation, and integration with patient records; forensic labs prioritize chain-of-custody and defensibility in legal contexts; correctional facilities favor rugged, easy-to-administer workflows; and specialized laboratories may require customizable testing menus. Finally, drug panel configuration shapes procurement and operational planning: customized and expanded panels meet the needs of complex clinical and forensic investigations, while fixed five- and ten-panel options address many routine workplace and roadside screening requirements, balancing comprehensiveness with cost-effectiveness.

A regional analysis that connects regulatory, infrastructural, and prevalence factors to differentiated deployment and adoption pathways across global markets

Regional differentiation reflects regulatory regimes, healthcare infrastructure maturity, and prevalence patterns that collectively shape adoption pathways and service delivery models. In the Americas, forensic and workplace testing frameworks are relatively mature, supporting a robust network of reference laboratories, diversified assay portfolios, and integrated reporting infrastructures. Investment in high-throughput instrumentation and chain-of-custody systems remains a priority as stakeholders respond to both public health initiatives and employer-driven compliance programs.

In Europe, the Middle East, and Africa region, regulatory harmonization efforts coexist with significant heterogeneity across jurisdictions, producing varied adoption curves for advanced instrumentation and confirmatory testing practices. Some markets emphasize stringent accreditation and legal defensibility, which supports demand for chromatography-based confirmation, while others prioritize scalable screening solutions that can be deployed across fragmented healthcare systems. In the Asia-Pacific region, rapid modernization of clinical and forensic laboratories, coupled with expanding public health surveillance, is driving interest in both high-resolution mass spectrometry and decentralized sample collection strategies. This region also presents opportunities to localize supply chains and develop service models that address diverse logistical and training needs across urban and rural settings. Across all regions, interoperability, workforce competency, and regulatory alignment remain critical enablers for scaling reliable testing services.

Insights into competitive strengths and service differentiation that determine how companies capture value across instrument reliability, assay depth, and digital enablement

Competitive dynamics in the era of sophisticated analytical platforms place a premium on integrated service offerings, reliable post-sale support, and collaborative research partnerships. Leading instrument manufacturers compete on analytical performance, user interface design, and the ecosystem of certified consumables that reduce variability and simplify validation. Vendors that provide robust training, rapid technical support, and flexible service contracts gain traction among laboratories that face staffing constraints and need predictable uptime for high-throughput operations.

At the same time, diagnostic and laboratory services providers differentiate through specialized assay development, customizable panel configurations, and fast turnarounds tailored to clinical, forensic, and correctional use cases. Collaborations between instrument vendors and assay developers are enabling bundled solutions that lower barriers to adopting advanced methodologies. Additionally, software and informatics companies that offer laboratory information management, result interpretation aids, and connectivity to health systems play an increasingly strategic role by improving workflow efficiency and ensuring compliance with reporting standards. Overall, companies that combine instrument excellence with lifecycle support, assay depth, and digital enablement are best positioned to serve the evolving needs of diverse end users.

Actionable strategic priorities for industry leaders to enhance testing reliability, supply resilience, workforce capability, and regulatory engagement

Leaders in the drug of abuse testing ecosystem should prioritize three parallel actions to strengthen resilience and capture emerging opportunities. First, invest in modular, hybrid testing architectures that combine immunoassay screening with chromatography-based confirmation and incorporate both centralized and decentralized sample workflows. This approach allows organizations to optimize cost and turnaround time while maintaining analytical defensibility for forensic and clinical applications. Second, enhance supply chain transparency and contractual flexibility by diversifying supplier relationships, negotiating extended support terms, and building contingency inventories for critical consumables. Such measures mitigate exposure to import duty fluctuations and logistical disruptions.

Third, develop workforce capability and digital proficiency through targeted training programs and investments in laboratory informatics that streamline reporting, quality management, and regulatory compliance. By strengthening technical competencies and data workflows, organizations can scale advanced testing modalities and integrate them into broader clinical and public health initiatives. Finally, engage proactively with policymakers and standard-setting bodies to shape practical, evidence-based guidelines for emerging substances and novel sample types. Taken together, these actions create a foundation for operational stability, analytical excellence, and adaptive commercial strategies in a shifting policy and technological environment.

A transparent, multi-method research approach combining stakeholder interviews, technical validation evidence, and regulatory review to underpin practical recommendations

The research underpinning this executive summary synthesizes primary interviews with laboratory directors, procurement managers, and forensic specialists together with secondary analysis of recent peer-reviewed literature, regulatory guidance, and public health surveillance reports. Methodological rigor derives from triangulating qualitative insights with documented performance attributes of assay technologies and instrumentation across multiple independent validation studies. Case examples and vendor capability assessments were reviewed to identify recurring operational themes, such as workflow integration, maintenance models, and training needs.

Throughout the analysis, particular attention was paid to ensuring reproducibility and transparency: source types and study selection criteria guided evidence weighting, and sensitivity checks addressed potential biases stemming from vendor-provided information. Where regulatory interpretations were discussed, the assessment relied on publicly available policy documents and consensus statements from professional societies. This blended approach supports balanced conclusions while acknowledging the heterogeneity of practice environments and the pace of technological change.

Concluding synthesis on how integrated technological adoption, supply chain planning, and workforce development will determine future testing reliability and impact

In summary, the drug of abuse testing domain is at a pivotal moment where technological capability, policy shifts, and end-user diversity converge to redefine operational norms. Laboratories and vendors face both the challenge of integrating sophisticated analytical platforms and the opportunity to deliver higher-confidence results that better serve clinical care, forensic processes, and public safety. Supply chain pressures and changing trade policies require proactive procurement and contingency planning, while regional differences demand context-sensitive deployment strategies.

Moving forward, success will favor organizations that adopt hybrid testing models, invest in workforce development and digital workflows, and build collaborative partnerships across the value chain. By aligning technological investments with practical considerations around sample types, end-user needs, and regulatory expectations, stakeholders can enhance testing reliability and ensure that results remain actionable in clinical, legal, and occupational contexts.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug of Abuse Testing Market, by Sample Type

  • 8.1. Hair
  • 8.2. Oral Fluid
  • 8.3. Urine

9. Drug of Abuse Testing Market, by Test Technology

  • 9.1. Chromatography
    • 9.1.1. Gc-Ms
    • 9.1.2. Lc-Ms
      • 9.1.2.1. Lc-Ms/Ms
      • 9.1.2.2. Lc-Qtof
  • 9.2. Immunoassay

10. Drug of Abuse Testing Market, by Drug Panel

  • 10.1. Customized Panel
  • 10.2. Expanded Panel
  • 10.3. Five Panel
  • 10.4. Ten Panel

11. Drug of Abuse Testing Market, by End User

  • 11.1. Clinical Laboratory
  • 11.2. Correctional Facility
  • 11.3. Forensic Laboratory
  • 11.4. Hospital

12. Drug of Abuse Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Drug of Abuse Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Drug of Abuse Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Drug of Abuse Testing Market

16. China Drug of Abuse Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AccuBioTech Co., Ltd.
  • 17.7. American Bio Medica Corporation
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. Clinical Reference Laboratory, LLC
  • 17.10. Cordant Health Solutions Inc.
  • 17.11. Danaher Corporation
  • 17.12. Dragerwerk AG & Co. KGaA
  • 17.13. Express Diagnostics International Inc.
  • 17.14. F. Hoffmann-La Roche Ltd.
  • 17.15. Laboratory Corporation of America Holdings (LabCorp)
  • 17.16. LGC Group Holdings Ltd.
  • 17.17. LifeLoc Technologies, Inc.
  • 17.18. MP Biomedicals, LLC
  • 17.19. Omega Laboratories, Inc.
  • 17.20. OraSure Technologies, Inc.
  • 17.21. Precision Diagnostics Inc.
  • 17.22. Premier Biotech, Inc.
  • 17.23. Psychemedics Corporation
  • 17.24. Quest Diagnostics Incorporated
  • 17.25. Randox Laboratories Ltd.
  • 17.26. Siemens Healthineers AG
  • 17.27. SureScreen Diagnostics Ltd.
  • 17.28. Thermo Fisher Scientific Inc.
  • 17.29. Wondfo Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG OF ABUSE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG OF ABUSE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HAIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY ORAL FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GC-MS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS/MS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY LC-QTOF, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CUSTOMIZED PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY EXPANDED PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FIVE PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY TEN PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CLINICAL LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY CORRECTIONAL FACILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY FORENSIC LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 129. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 130. GCC DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 150. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 151. G7 DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 157. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 158. NATO DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL DRUG OF ABUSE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA DRUG OF ABUSE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY TEST TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY LC-MS, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY DRUG PANEL, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA DRUG OF ABUSE TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)